A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Farletuzumab (Primary) ; Carboplatin; Doxorubicin; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Morphotek
- 08 Feb 2017 Planned End Date changed from 1 May 2020 to 1 May 2021.
- 08 Feb 2017 Planned primary completion date changed from 1 Aug 2018 to 1 May 2019.
- 03 Oct 2016 Planned End Date changed from 1 Aug 2019 to 1 May 2020.